Related Experiment Video
Updated: Jun 27, 2025
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
[Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer]
Renske Altena1, Mikael Nilsson2, Viveka Bergman3
1docent, biträdande överläkare, onkologi och internmedicin, ME bröst-, endokrina tumörer och sarkom, Karolinska Comprehensive Cancer Center, Karolinska universitetssjukhuset Solna.
Abstract:
Anaplastic and poorly differentiated thyroid cancer (ATC, PDTC) are rare and highly aggressive tumors that historically have been associated with a short life expectancy and low chance of cure. Molecular pathology and the introduction of highly effective targeted drugs have revolutionized the possibilities of management of patients with ATC and PDTC, with BRAF and MEK inhibitors as the most prominent example. Here we provide updated recommendations regarding diagnostics and management, including primary surgical management and targeted therapies based on specific molecular pathological findings.
Insights
Anaplastic and poorly differentiated thyroid cancer (ATC, PDTC) management has improved with targeted therapies like BRAF and MEK inhibitors. Updated recommendations cover diagnostics, surgery, and molecularly guided treatments for these aggressive tumors.
Area of Science:
- Oncology
- Molecular Pathology
- Endocrinology
Background:
- Anaplastic and poorly differentiated thyroid cancer (ATC, PDTC) are rare, aggressive malignancies with historically poor prognoses.
- Advances in molecular pathology have identified key drivers in ATC and PDTC, enabling targeted treatment strategies.
- Targeted therapies, particularly BRAF and MEK inhibitors, have shown significant promise in improving outcomes for patients with these cancers.
Purpose of the Study:
- To provide updated recommendations for the diagnosis and management of ATC and PDTC.
- To integrate molecular pathology findings into treatment decision-making for ATC and PDTC.
- To outline strategies for primary surgical management and targeted therapies in ATC and PDTC.
Main Methods:
- Review of current literature and clinical trial data on ATC and PDTC.
- Analysis of molecular pathology findings relevant to targeted therapy selection.
- Development of evidence-based recommendations for diagnostic and therapeutic approaches.
Main Results:
- Molecular profiling is crucial for identifying actionable mutations in ATC and PDTC.
- BRAF and MEK inhibitors represent a significant therapeutic advance for patients with specific molecular alterations.
- A multidisciplinary approach combining surgery and targeted therapy improves patient outcomes.
Conclusions:
- Targeted therapies based on molecular pathology have transformed the management of ATC and PDTC.
- Updated guidelines emphasize the importance of molecular diagnostics for personalized treatment.
- Optimized surgical and targeted treatment strategies offer improved survival and cure rates for ATC and PDTC.
